François‐Clément Bidard

← Back to Université de Versailles Saint-Quentin-en-Yvelines

ORCID

Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.

Selected research works

Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.

1. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data

   2014 · 838 citations

2. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

   2022 · 757 citations

3. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group

   2022 · 753 citations

4. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle

   2014 · 386 citations

5. Circulating Tumor Cell Detection Predicts Early Metastatic Relapse After Neoadjuvant Chemotherapy in Large Operable and Locally Advanced Breast Cancer in a Phase II Randomized Trial

   2008 · 369 citations

6. Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer

   2016 · 363 citations

7. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial

   2022 · 349 citations

8. Microfluidic sorting and multimodal typing of cancer cells in self-assembled magnetic arrays

   2010 · 337 citations

9. Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study

   2017 · 315 citations

10. A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)

    2016 · 283 citations

11. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients

    2011 · 281 citations

12. Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis

    2018 · 277 citations

13. The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper

    2018 · 274 citations

14. Circulating tumor DNA as a non‐invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types

    2014 · 269 citations

15. Neutrophil extracellular traps formed during chemotherapy confer treatment resistance via TGF-β activation

    2023 · 266 citations

16. Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials

    2012 · 237 citations

17. Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer

    2009 · 232 citations

18. Circulating tumor cells: clinical validity and utility

    2017 · 219 citations

19. Patient-Specific Circulating Tumor DNA Detection during Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer

    2017 · 213 citations

20. Imlunestrant with or without Abemaciclib in Advanced Breast Cancer

    2024 · 204 citations

21. Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma

    2013 · 201 citations

22. Clinical utility of circulating tumor cells: an update

    2020 · 199 citations

23. Circulating tumor cells in breast cancer

    2016 · 197 citations

24. Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy

    2018 · 196 citations

25. Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial

    2013 · 192 citations

← Return to the university profile